• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

重新定义癌症研究，以实现治疗突破。

Redefining cancer research for therapeutic breakthroughs.

机构信息

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

出版信息

Br J Cancer. 2024 Apr;130(7):1078-1082. doi: 10.1038/s41416-024-02634-6. Epub 2024 Feb 29.

DOI:10.1038/s41416-024-02634-6
PMID:38424166
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10991368/
Abstract

Cancer research has played a pivotal role in improving patient outcomes. However, despite the significant investment in fundamental cancer research over the past few decades, the translation of funding into substantial advancements in cancer treatment has been limited. This perspective article employs a detailed analysis to outline strategies for promoting innovation and facilitating discoveries within the field of cancer research.

摘要

癌症研究在改善患者预后方面发挥了关键作用。然而，尽管在过去几十年中对基础癌症研究进行了大量投资，但将资金转化为癌症治疗方面的实质性进展却有限。本文通过详细分析，提出了促进癌症研究领域创新和发现的策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca80/10991368/5bb3b2f5d594/41416_2024_2634_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca80/10991368/2a2d42c0d6fc/41416_2024_2634_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca80/10991368/77b879d273d0/41416_2024_2634_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca80/10991368/5bb3b2f5d594/41416_2024_2634_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca80/10991368/2a2d42c0d6fc/41416_2024_2634_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca80/10991368/77b879d273d0/41416_2024_2634_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca80/10991368/5bb3b2f5d594/41416_2024_2634_Fig3_HTML.jpg

相似文献

1
Redefining cancer research for therapeutic breakthroughs.重新定义癌症研究，以实现治疗突破。
Br J Cancer. 2024 Apr;130(7):1078-1082. doi: 10.1038/s41416-024-02634-6. Epub 2024 Feb 29.
2
Friend or foe: assessing the value of animal models for facilitating clinical breakthroughs in complement research.敌友之间：评估动物模型在推动补体研究临床突破方面的价值。
J Clin Invest. 2025 Jun 16;135(12). doi: 10.1172/JCI188347.
3
Fabricating mice and dementia: opening up relations in multi-species research制造小鼠与痴呆症：开启多物种研究中的关联
4
The Welsh Institute of Performance Science: A Decade of Integrated Knowledge Translation in Elite Sport.威尔士运动表现科学研究所：精英体育领域十年的综合知识转化
Sports Med. 2025 Apr 29. doi: 10.1007/s40279-025-02210-9.
5
Assessing excellence in translational cancer research: a consensus based framework.评估转化性癌症研究中的卓越性：一个基于共识的框架。
J Transl Med. 2013 Oct 29;11:274. doi: 10.1186/1479-5876-11-274.
6
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理（2025年结石病专家共识）
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
7
New horizons in B-cell lymphoma immunotherapy: From immune checkpoints to precision medicine.B细胞淋巴瘤免疫治疗的新视野：从免疫检查点到精准医学
Neoplasia. 2025 Jun 30;67:101206. doi: 10.1016/j.neo.2025.101206.
8
Unraveling molecular advancements in chordoma tumorigenesis and treatment response: a review of scientific discoveries and clinical implications.解析脊索瘤肿瘤发生和治疗反应中的分子进展：科学发现与临床意义的综述。
Neurosurg Focus. 2024 May;56(5):E18. doi: 10.3171/2024.2.FOCUS2417.
9
Outcome measurement in pemphigus clinical research: a scoping review on heterogeneity in outcome reporting and definitions.天疱疮临床研究中的结局测量：关于结局报告和定义异质性的范围综述
Br J Dermatol. 2025 Apr 18. doi: 10.1093/bjd/ljaf152.
10
Shaping the future of primary care in Canada: trainee insights on patient and public engagement in health system transformation research.塑造加拿大初级医疗的未来：实习生对患者及公众参与卫生系统转型研究的见解
Health Res Policy Syst. 2025 Aug 4;23(1):98. doi: 10.1186/s12961-025-01366-0.

引用本文的文献

1
Photodynamic Therapy and Tumor Microenvironment-Targeting Strategies: A Novel Synergy at the Frontier of Cancer Treatment.光动力疗法与肿瘤微环境靶向策略：癌症治疗前沿的新型协同作用
Int J Mol Sci. 2025 Sep 3;26(17):8588. doi: 10.3390/ijms26178588.
2
Standardized sulforhodamine b colorimetric cell proliferation assay for anticancer activity screening in educational and research laboratories.用于教育和研究实验室抗癌活性筛选的标准化磺酰罗丹明b比色细胞增殖测定法。
MethodsX. 2025 Jun 30;15:103469. doi: 10.1016/j.mex.2025.103469. eCollection 2025 Dec.
3
Do PGCCs in Solid Tumors Appear Due to Treatment-related Stress or Clonal Expansion of CSCs that Survive Oncotherapy?

本文引用的文献

1
Progress in the field of noninvasive diagnostics for colorectal cancer: a systematic review for the accuracy of blood-based biomarkers for detection of advanced pre-cancerous lesions.结直肠癌非侵入性诊断领域的进展：基于血液的生物标志物检测晚期癌前病变准确性的系统评价
Expert Rev Mol Diagn. 2023 Jul-Dec;23(12):1233-1250. doi: 10.1080/14737159.2023.2290646. Epub 2023 Dec 15.
2
Trends in the approval of cancer therapies by the FDA in the twenty-first century.二十一世纪 FDA 批准癌症疗法的趋势。
Nat Rev Drug Discov. 2023 Aug;22(8):625-640. doi: 10.1038/s41573-023-00723-4. Epub 2023 Jun 21.
3
Cancer Moonshot Plan Announced.
实体瘤中的肿瘤干细胞样细胞（PGCCs）是由治疗相关应激导致的，还是由抗癌治疗后存活的肿瘤干细胞（CSCs）克隆性扩增产生的？
Stem Cell Rev Rep. 2025 May 8. doi: 10.1007/s12015-025-10891-y.
4
Misconceptions Thrive in the Field of Cancer as Technological Advances Continue to Confuse Stem Cell Biology.随着技术进步不断混淆干细胞生物学，癌症领域中误解盛行。
Stem Cell Rev Rep. 2025 Apr 16. doi: 10.1007/s12015-025-10880-1.
5
Recent Survival Gains in Stage IV NSCLC by Sociodemographic Strata.IV期非小细胞肺癌患者近期按社会人口统计学分层的生存获益情况。
JTO Clin Res Rep. 2025 Jan 17;6(4):100798. doi: 10.1016/j.jtocrr.2025.100798. eCollection 2025 Apr.
6
Discovery and development of steroidal enzyme inhibitors as anti-cancer drugs: state-of-the-art and future perspectives.甾体酶抑制剂作为抗癌药物的发现与开发：现状与未来展望。
J Enzyme Inhib Med Chem. 2025 Dec;40(1):2483818. doi: 10.1080/14756366.2025.2483818. Epub 2025 Apr 2.
7
Young-onset metastatic colorectal cancer: an opportunity and a vision for progress in cancer.青年起病的转移性结直肠癌：癌症进展的机遇与展望
Med Oncol. 2025 Mar 8;42(4):95. doi: 10.1007/s12032-025-02640-5.
8
Integrating alternative therapies in overcoming chemotherapy resistance in tumors.整合替代疗法以克服肿瘤的化疗耐药性。
Mol Biol Rep. 2025 Feb 17;52(1):239. doi: 10.1007/s11033-025-10361-1.
9
On-demand release of encapsulated ZnO nanoparticles and chemotherapeutics for drug delivery applications.用于药物递送应用的包封型氧化锌纳米颗粒和化疗药物的按需释放。
RSC Pharm. 2024 Nov 6;2(1):82-93. doi: 10.1039/d4pm00189c. eCollection 2025 Jan 21.
10
Therapeutic Potential of Natural Compounds to Modulate WNT/β-Catenin Signaling in Cancer: Current State of Art and Challenges.天然化合物调节癌症中WNT/β-连环蛋白信号传导的治疗潜力：现状与挑战
Int J Mol Sci. 2024 Nov 28;25(23):12804. doi: 10.3390/ijms252312804.
癌症“登月计划”宣布。
JAMA. 2023 May 2;329(17):1443. doi: 10.1001/jama.2023.6252.
4
Multifactorial Diseases of the Heart, Kidneys, Lungs, and Liver and Incident Cancer: Epidemiology and Shared Mechanisms.心脏、肾脏、肺和肝脏的多因素疾病与新发癌症：流行病学及共同机制
Cancers (Basel). 2023 Jan 25;15(3):729. doi: 10.3390/cancers15030729.
5
Cancer statistics, 2023.癌症统计数据，2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
6
Papers and patents are becoming less disruptive over time.随着时间的推移，论文和专利的颠覆性越来越小。
Nature. 2023 Jan;613(7942):138-144. doi: 10.1038/s41586-022-05543-x. Epub 2023 Jan 4.
7
Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy.价格与偏见？嵌合抗原受体（CAR）T 细胞疗法的价值。
Int J Environ Res Public Health. 2022 Sep 28;19(19):12366. doi: 10.3390/ijerph191912366.
8
Cancer vaccines: the next immunotherapy frontier.癌症疫苗：下一个免疫治疗前沿。
Nat Cancer. 2022 Aug;3(8):911-926. doi: 10.1038/s43018-022-00418-6. Epub 2022 Aug 23.
9
Single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer tumors.原发和转移性结直肠癌肿瘤的单细胞基因组和转录组图谱。
Genome Med. 2022 Aug 16;14(1):93. doi: 10.1186/s13073-022-01093-z.
10
Should Targeted Therapy Be Continued in BRAF-Mutant Melanoma Patients after Complete Remission?BRAF 突变型黑色素瘤患者完全缓解后是否应继续进行靶向治疗？
Dermatology. 2022;238(3):517-526. doi: 10.1159/000518718. Epub 2021 Oct 27.